TriHealth achieves EMRAM Stage 7

Four TriHealth hospitals have achieved Stage 7 EMR Adoption Model Awards, along with 131 of its associated ambulatory clinics located throughout Ohio, Kentucky and Indiana achieving Stage 7 Ambulatory Awards.

HIMSS Analytics developed the EMR Adoption Model in 2005 as a methodology for evaluating the progress and impact of EMR systems for hospitals in the HIMSS Analytics Database. Stage 7 indicates the top level and an advanced patient record environment. HIMSS Analytics developed the EMR Ambulatory Adoption Model in 2011.

During the first quarter of 2014, only 3.1 percent of the more than 5,400 U.S. hospitals in the HIMSS Analytics® Database received the Stage 7 Award, and only 4.54 percent of the more than 24,200 ambulatory clinics in the HIMSS Analytics® Database received the Stage 7 Ambulatory Award.

TriHealth, one of the fastest-growing health systems in Greater Cincinnati, has more than 500 doctors and 11,000 other employees. It operates four hospitals (Good Samaritan in University Heights, Bethesda North in Montgomery, Bethesda Butler in Hamilton and TriHealth Evendale) and more than 130 other locations.

“This is an excellent deployment of an enterprise EHR that proved to be transformational,” said John P. Hoyt, executive vice president of HIMSS Analytics. “TriHealth has been an early adopter of technologies that are just beginning to become mainstream. This is truly an organization that enthusiastically embraces technology to support their core mission.”

TriHealth will be recognized at the 2015 Annual HIMSS Conference & Exhibition on April 12-16, 2015, in Chicago.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.